drugset
drugset / Trial / NCT07214987

PDT For Induction Therapy For Head And Neck Cancer

NCT07214987 ↗

Phase 2 Recruiting 26 enrolled Massachusetts General Hospital Coherus Oncology, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

This research study is being done to assess the safety and tolerability of toripalimab in combination with cisplatin and docetaxel (PDT) induction therapy for patients with CPS-positive locally advanced head and neck squamous cell carcinoma (HNSCC).

Timeline

Start
2026-03-09
Primary completion
2027-12-31
Completion
2029-09-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified — Intravenous
Subject Docetaxel Small molecule — Intravenous
Subject Toripalimab Monoclonal antibody — Intravenous

Indications

head and neck squamous cell carcinoma